Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein kinase cAMP-dependent type I regulatory subunit beta (PRKAR1B) is a key regulatory subunit of the PKA holoenzyme, which mediates cellular responses to cAMP. The PKA holoenzyme consists of two regulatory subunits (including PRKAR1B as RIβ) and two catalytic subunits. Upon cAMP binding, the complex dissociates, allowing the catalytic subunits to phosphorylate diverse protein targets. PRKAR1B is most highly expressed in the nervous system, especially cerebral cortex and hypothalamus, and its dysfunction causes neurodevelopmental disorders and contributes to tumorigenesis in some contexts. It serves as a cAMP receptor within the cell and anchors the PKA complex to specific subcellular locations via AKAP proteins, modulating key processes such as metabolism, ion transport, transcription, and neuronal signaling
Drugs that **modulate PKA activity** (by influencing cAMP levels, such as agonists of Gs-coupled GPCRs, PDE inhibitors, or adenylyl cyclase activators) indirectly affect PRKAR1B function as part of the PKA holoenzyme
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein kinase cAMP-dependent type I regulatory subunit beta (PRKAR1B).